What is it about?
Peter Libby MD, reflects on CANTOS and a new era of personalised medicine
Featured Image
Photo by Emily Karakis on Unsplash
Why is it important?
For many basic science labs around the world the hotly-anticipated findings of the CANTOS trial delivered at the ESC Congress in 2017 were welcomed as an affirmation of years, if not decades of work on inflammation. It was an important moment for Peter Libby MD, Mallinckrodt Professor of Medicine at Harvard Medical School and long-time Chief of Cardiovascular Medicine at Brigham and Women’s Hospital in Boston, Massachusetts, USA. Investigators in his own lab have been engaged in inflammation research for many years.
Perspectives
An important perspective from a crucial investigator
Judith Ozkan
Read the Original
This page is a summary of: Peter Libby MD and CANTOS, European Heart Journal, May 2018, Oxford University Press (OUP),
DOI: 10.1093/eurheartj/ehy177.
You can read the full text:
Resources
Contributors
The following have contributed to this page
